300430 Beijing Chieftain Control Engineering Technology
- 16.54
- +0.37+2.29%
Beijing Chieftain Control Engineering Technology News
Chengyitong (300430.SZ): The core product automated biological fermentation control system has many applications in the field of synthetic biology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Are there synthetic biological-related technologies currently being developed by the company?” The company replied that downstream customers in the company's intelligent manufacturing sector mainly include pharmaceutical and biological manufacturing companies. Biomaneling is mainly a production method using synthetic biotechnology as an important technical support and biological fermentation process as an important means of implementation. The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology. Driven by synthetic biotechnology and green biological manufacturing, 202
Chengyitong (300430.SZ): Currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of invasive technology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Can the brain-computer products the company is developing regenerate insulin to treat diabetes?” The company replied that currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of intrusive technology. In planning non-invasive technology, the company integrates existing rehabilitation products with brain-computer interfaces to achieve product upgrades, thereby providing more effective rehabilitation services for patients with neurological diseases. In the future, the company will also focus on the application of brain-computer interfaces in other medical fields
Chengyitong (300430.SZ) announced first-quarter results, net profit of 307.813 million yuan, an increase of 37.71%
Chengyitong (300430.SZ) released its report for the first quarter of 2024, achieving 2.68 operating income during the reporting period...
Chengyitong (300430.SZ) issued 2023 annual results, with net profit of 170 million yuan, an increase of 36.30% over the previous year
Chengyitong (300430.SZ) released its 2023 annual report. The company achieved operating income of 11 during the reporting period...
Chengyitong (300430.SZ): Long Zhijie has now developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices
Gelonghui, April 12, 丨 Chengyitong (300430.SZ) said on the investor interactive platform that the company has always attached great importance to technical reserves and product development in brain science. The rehabilitation industry is one of the most successful and extensive fields of application of related technology. Long Zhijie began exploring related technologies in 2020. Currently, it has developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices, and established Beijing Brain Link Technology Co., Ltd. on March 28, 2024. In the future, it will rely on Brain Connect Technology's platform to further explore brain-computer interface related technology and carry out related technical research and product development work, for big
Chengyitong (300430.SZ): Will rely on BrainLink Technology's platform to explore brain-computer interface-related technologies in depth
Gelonghui, April 8, 丨 Chengyitong (300430.SZ) said on the interactive platform that the company established Beijing Brain Connect Technology Co., Ltd. on March 28, 2024. The company will rely on BrainConnect Technology's platform to thoroughly explore brain-computer interface-related technologies, first using Longzhijie's existing products to achieve non-invasive brain function upgrades, and support R&D teams to explore invasive brain-computer technology research and development. The company will continue to cooperate deeply with senior teams from well-known universities to actively explore the application of brain science in the field of rehabilitation and medicine.
Chengyitong (300430.SZ): Xinting Zhizhen's shareholding ratio fell below 5%
Gelonghui, Feb. 23, 丨 Chengyitong (300430.SZ) announced that the company recently received the “Simplified Equity Change Report” issued by Xinting Zhizhen and learned that Xinting Zhizhen reduced its holdings of the company's shares by 5,254,500 shares through bulk transactions on the Shenzhen Stock Exchange. After this transaction, Xinting Zhizhen's share holding ratio was reduced from 6.923404% to 4.999976%. It is no longer a shareholder holding more than 5% of the company's shares.
Chengyitong (300430.SZ): Controlling shareholders pledge an additional 4.5 million shares
Gelonghui, Feb. 8, 丨 Chengyitong (300430.SZ) announced that the company recently received a notice from Beijing Liwei Investment Co., Ltd. (“Liwei”), the controlling shareholder of the company, and learned that the company's shares held by it have applied for supplementary equity pledge business. The number of shares pledged this time is 4.5 million shares.
Chengyitong (300430.SZ): Net profit is expected to increase 17.07%-49.94% year-on-year in 2023
On February 6, Gelonghui | Chengyitong (300430.SZ) announced that net profit for 2023 is estimated to be 146 million yuan to 187 million yuan, up 17.07%-49.94% from the same period last year, after deducting non-net profit of 121 million yuan to 162 million yuan, an increase of 6.40%-42.45% over the same period last year. In the intelligent manufacturing sector, the company continues to expand its business in the fields of chemical synthesis, traditional Chinese medicine and plant extraction, powder preparation, and intelligent packaging based on intelligent manufacturing in the field of biofermentation, and its advantageous business, while vigorously developing and innovating, along with new products such as “online near-infrared spectrometers”
Liweite, the controlling shareholder of Chengyitong (300430.SZ), and Leung Hok-yin, the actual controller, released the pledge of 19841,300 shares
Chengyitong (300430.SZ) announced that the company received Beijing Liweite Investment Co., Ltd., the controlling shareholder of the company (...
Chengyitong (300430.SZ): Net profit of 128 million yuan for the first three quarters increased 69.68% year-on-year
Glonghui, October 26丨Chengyitong (300430.SZ) announced its third quarter report. Revenue was 928 million yuan, up 33.57% year on year, net profit was 128 million yuan, up 69.68% year on year, after deducting non-net profit of 120 million yuan, up 71.18% year on year, and basic earnings per share were 0.47 yuan.
Chengyitong (300430.SZ) issued an advance increase. Net profit for the first three quarters is expected to be 124 million yuan to 135 million yuan, an increase of 65% to 80% over the previous year
Chengyitong (300430.SZ) disclosed the performance forecast for the first three quarters of 2023. The company expects the first three quarters to belong to...
Chengyitong (300430.SZ) released first-half results, net profit of 74.2703 million yuan, an increase of 43.88%
Chengyitong (300430.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income of 6...
Chengyitong (300430.SZ): Confident to successfully achieve this year's performance goals
GLONGHUI, August 9丨Some investors asked Chengyitong (300430.SZ), “Your healthcare business is developing strongly in various markets. It has already been predicted that performance and profit for the first half of the year will grow by around 50%. From now on, can you maintain this growth rate or exceed expectations throughout the year?” Cheng Yitong replied that according to the company's 2021 equity incentive plan, this year's performance target profit will reach at least 168 million yuan. The company operated steadily and achieved good performance growth in the first half of the year. Currently, the two sectors are developing well, and there are plenty of orders in place, and we are confident that we will successfully complete this year's performance target.
Chengyitong (300430.SZ) is forecasted to increase. Net profit for the first half of the year is expected to be 69.36 million yuan to 78.97 million yuan, up 34% to 53% over the previous year
According to the Zhitong Finance App, Chengyitong (300430.SZ) disclosed the 2023 semi-annual results forecast. The company expects net profit attributable to shareholders of listed companies in the first half of the year to RMB 69.36 million to RMB 78.97 million, up 34% to 53% year on year; net profit after deducting non-recurring profit and loss will be RMB 67.29 million to RMB 76.9 million, up 40% to 60% year on year. During the reporting period, the company focused on developing its main business, striving to improve the company's profitability and achieve steady growth in business performance. In the intelligent manufacturing sector, the company continues to vigorously expand chemistry based on intelligent manufacturing business in the field of biofermentation, an advantageous business
Chengyitong (300430.SZ) plans to distribute 0.2 yuan for 10 shares to remove interest on July 12
Zhitong Finance App News, Chengyitong (300430.SZ) announced that the company's 2022 annual equity distribution plan: pay 0.20 yuan (tax included) for every 10 shares to all shareholders. Exclusion and dividend date is: July 12, 2023.
The latest announcement of Chengyitong: the net profit of 2021 is expected to increase by 60.00% PUE 79.84%.
Chengyitong disclosed the annual performance forecast for 2021, which is expected to achieve a net profit of 96.62 million yuan to 109 million yuan belonging to shareholders of listed companies in 2021, an increase of 60.00% to 79.84% over the same period last year. It is expected that net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses in 2021 is 85.62 million yuan to 97.6 million yuan, an increase of 66.32% to 89.59% over the same period last year. The chairman of the company is Liang Kai. Mr. Liang Kai: born in 1969, Chinese nationality, no permanent residence abroad, bachelor's degree, once worked in 502 Institute of the Fifth Academy of the Ministry of Aerospace. Since November 1998
Chengyitong: 12 institutions, including Oriental Fund and China-Canada Fund, investigated our company on January 12.
Chengyitong (300430) issued a notice on January 12, 2022: Oriental Fund, China Canada Fund, founder Fubon Fund, CITIC Construction Investment Management, founder Securities Management, Huaxia Jiuying Capital Management, Shanghai Jingling Investment, Societe Generale Securities, Happiness Life, Guoshou Security Fund Management Co., Ltd., Jianxin Pension Management Company and China United Insurance Group Co., Ltd. conducted a survey of our company on January 12, 2022. The main content of this survey: Q: what is the development direction of the company's intelligent manufacturing plate and what are the main customer groups? Answer: the main customers of the company's intelligent manufacturing business are pharmaceutical and biological products production enterprises. From
Luo Yuanlong, a shareholder of Chengyitong (300430.SZ), and his concerted action hostage 9.6 million shares.
Zhitong Financial APP News, Chengyitong (300430.SZ) issued an announcement that the company recently received notice from shareholders Luo Yuanlong, Luo Xiaobing and Luo Xiaozhu, who held more than 5 per cent of the shares in the company, and learned that part of the company's shares had been pledged. A total of 9.6 million shares were pledged this time, accounting for 3.53 per cent of the company's total share capital.
Chengyitong (300430.SZ): it is proposed to increase the capital of long Zhijie by 90 million yuan to expand the scale of production and operation, supplement daily liquidity, etc.
300430.SZ announced that in order to further enhance the business development ability and financial strength of Guangzhou long Zhijie Technology Co., Ltd. ("long Zhijie") and ensure the sustainable and healthy development of long Zhijie, the company plans to use its own funds to increase RMB 90 million to long Zhijie, mainly for expanding the scale of production and operation and replenishing daily liquidity.
Analysis
Price Target
No Data
